Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) was the recipient of a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 13,000 shares, a decline of 93.3% from the September 30th total of 194,477 shares. Based on an average daily trading volume, of 6,323 shares, the short-interest ratio is currently 2.1 days.
Innovent Biologics Trading Down 7.8%
IVBXF stock traded down $0.90 during mid-day trading on Monday, hitting $10.65. 1,620 shares of the company were exchanged, compared to its average volume of 3,715. Innovent Biologics has a 12-month low of $9.10 and a 12-month high of $15.01. The business has a fifty day simple moving average of $12.49 and a 200-day simple moving average of $11.23.
Innovent Biologics Company Profile
Innovent Biologics, Inc is a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of medicines for cancer, autoimmune diseases and metabolic disorders. The company develops biologic therapies, including monoclonal antibodies, antibody-drug conjugates and other advanced treatments, with the goal of providing innovative and more accessible medicines.
Its marketed portfolio includes sintilimab, an immunotherapy developed in collaboration with Eli Lilly and marketed in China under the brand name Tyvyt, as well as biosimilar and biologic products for oncology and immune-related conditions.
See Also
- Five stocks we like better than Innovent Biologics
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
